The Treatment of R/R cHL in the Era of Checkpoint Inhibitors

The Treatment of R/R cHL in the Era of Checkpoint Inhibitors
The Treatment of R/R cHL in the Era of Checkpoint Inhibitors
CME, CPE
Catherine Diefenbach, MD
Release Date: November 28, 2018
Expiration Date: November 28, 2019
The treatment landscape for relapsed/refractory classical Hodgkin lymphoma (R/R cHL) is expanding thanks to the development of immunotherapies like checkpoint inhibitors. In this activity, Dr. Catherine Diefenbach summarizes current salvage treatment options for R/R cHL—including their benefits and risks—and discusses the efficacy and safety of immunotherapy in the management of this difficult-to-treat patient population.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb, Merck and Co., Inc., and Seattle Genetics, Inc.
Begin, Earn CreditView Only, No CreditGet Certificate
 

Managing HL would like to recognize and thank Bristol-Myers Squibb, Merck & Co., Inc., and Seattle Genetics for their educational support of ManagingHodgkinLymphoma.com in 2018.

©2019 MediCom Worldwide, Inc. All rights reserved